Outcome of extracorporeal photopheresis in mycosis fungoides patients is not predicted by quotients of systemic immune‐inflammatory biomarkers
Journal of Clinical Apheresis · 2022-08 · 37 (4) · 360-366
DOI: 10.1002/jca.21982 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Apheresis, online erschienen am 30.03.2022. Verfasst von Thilo Gambichler und 5 weiteren Autor:innen. Beteiligte Einrichtung: Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany. Hauptthemen laut MEDLINE: Mycosis Fungoides, Photopheresis, Skin Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Systemic immune‐inflammatory biomarkers (SIIBs) have not been studied in mycosis fungoides (MF) patients undergoing extracorporeal photopheresis (ECP).
Objective
The objective was to determine whether recently proposed SIIBs are suitable to predict ECP treatment outcome and overall prognosis of patients with MF.
Methods
Twenty‐nine MF patients were retrospectively evaluated who had undergone ECP. SIIBs included neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio, lymphocyte‐to‐monocyte ratio, and pan‐immune‐inflammation value.
Results
Lymphocyte count ( P = .021), CD4+/CD8+ cells ( P = .00006), CD4+/CD56+ NK cells ( P = .00008), and LDH levels ( P = .0041) significantly declined after 6‐month ECP. We could not detect significant cutoff values for baseline SIIBs capable of predicting advanced disease, overall response to 6‐month ECP, or 5‐year lymphoma‐specific (LS) survival ( P > .05). Circulating baseline counts of CD4+/CD7‐ cells (cutoff: ≤ 12.2; P = .010) and CD4+/CD26‐ cells (cutoff: ≤ 19.5; P < .0001) significantly predicted ECP treatment response after 6 months. Moreover, CD4+/CD8+ ratio (cutoff: > 1.34; P = .045) and increased thrombocyte counts (cutoff: >259 000; P = .010) were baseline predictors for 5‐year LS death.
Conclusion
ECP appears to be beneficial in early‐stage CTCL as well. Lower percentages of circulating CD4+/CD7‐ and CD4+/CD26‐ lymphocytes at baseline correlate with response to ECP. In this study, however, baseline SIIBs did not appear to serve as suitable biomarkers for the prediction of treatment outcome and LS survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.
ORCID-Profile: Thilo Gambichler
Zitieren
APA
Gambichler, T., Späth, J., Said, S., Scheel, C. H., Susok, L., & Stranzenbach, R. (2022). Outcome of extracorporeal photopheresis in mycosis fungoides patients is not predicted by quotients of systemic immune‐inflammatory biomarkers. Journal of Clinical Apheresis, 37(4), 360-366. https://doi.org/10.1002/jca.21982
Vancouver
Gambichler T, Späth J, Said S, Scheel CH, Susok L, Stranzenbach R. Outcome of extracorporeal photopheresis in mycosis fungoides patients is not predicted by quotients of systemic immune‐inflammatory biomarkers. Journal of Clinical Apheresis. 2022;37(4):360-366. doi:10.1002/jca.21982
BibTeX
@article{Gambichler2022,
author = {Gambichler, Thilo and Späth, Jan and Said, Shayda and Scheel, Christina H and Susok, Laura and Stranzenbach, Rene},
title = {Outcome of extracorporeal photopheresis in mycosis fungoides patients is not predicted by quotients of systemic immune‐inflammatory biomarkers},
journal = {Journal of Clinical Apheresis},
year = {2022},
volume = {37},
number = {4},
pages = {360--366},
doi = {10.1002/jca.21982}
}
EUVIMED